Heidelberg Pharma Reports Positive First Half-Year of 2026

Heidelberg Pharma AG has released its first half-year financial report for 2026, showcasing strong business progress. The company completed a Phase I dose escalation study with its leading candidate pamlectabart tismanitin for multiple myeloma, moving forward with Phase IIa trials. Financially, the firm improved its stability via a $20 million deal amendment with HealthCare Royalty and Soleus Capital, extending its cash runway to mid-2027.

Strategic collaborations with Takeda and Huadong yielded milestone payments, further bolstering finances. Notably, sales increased by 84% to EUR 9.2 million, lowering the net loss to EUR 3.4 million. Cost reductions and restructurings contributed to financial optimization. Despite the positive developments, the equity position remained negative.